Janus Henderson Group PLC Biomea Fusion, Inc. Transaction History

Janus Henderson Group PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.14 - $15.3 $5.27 Million - $19.5 Million	-1,274,078 Reduced 99.13%	11,200 $50,000
Q1 2024 May 15, 2024	SELL	$13.92 - $19.5 $6.03 Million - $8.44 Million	-432,967 Reduced 25.2%	1,285,278 $19.2 Million
Q4 2023 Feb 14, 2024	SELL	$8.37 - $19.8 $10.5 Million - $24.9 Million	-1,259,236 Reduced 42.29%	1,718,245 $24.9 Million
Q3 2023 Nov 14, 2023	BUY	$13.44 - $23.02 $1.7 Million - $2.92 Million	126,811 Added 4.45%	2,977,481 $41 Million
Q2 2023 Aug 14, 2023	SELL	$21.66 - $41.8 $5.75 Million - $11.1 Million	-265,387 Reduced 8.52%	2,850,670 $62.6 Million
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $2.44 Million - $11.6 Million	358,949 Added 13.02%	3,116,057 $96.6 Million
Q4 2022 Feb 14, 2023	SELL	$6.3 - $11.6 $468,594 - $862,808	-74,380 Reduced 2.63%	2,757,108 $23.2 Million
Q3 2022 Nov 14, 2022	SELL	$9.51 - $13.61 $194,118 - $277,807	-20,412 Reduced 0.72%	2,831,488 $27.7 Million
Q2 2022 Aug 15, 2022	SELL	$3.0 - $12.03 $2.82 Million - $11.3 Million	-941,428 Reduced 24.82%	2,851,900 $34.1 Million
Q1 2022 May 16, 2022	BUY	$4.39 - $9.03 $1.17 Million - $2.4 Million	266,042 Added 7.54%	3,793,328 $16.9 Million
Q4 2021 Feb 14, 2022	BUY	$7.22 - $12.72 $2.35 Million - $4.15 Million	325,921 Added 10.18%	3,527,286 $26 Million
Q3 2021 Nov 16, 2021	BUY	$10.0 - $15.99 $5.74 Million - $9.18 Million	573,983 Added 21.85%	3,201,365 $37.8 Million
Q2 2021 Aug 16, 2021	BUY	$13.65 - $20.93 $35.9 Million - $55 Million	2,627,382 New	2,627,382 $39.6 Million

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $117M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.